ePrints

Perioperative management of patients who are receiving a novel oral anticoagulant

Lookup NU author(s): Dr Aaron Liew

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The use of novel oral anticoagulants (NOACs) is increasing since these drugs are at least as efficacious and safe as vitamin K antagonists (VKAs) for the management of patients with non-valvular atrial fibrillation and venous thromboembolism. Compared with VKAs, NOACs have a faster onset and offset of action, a predictable and consistent pharmacokinetic profile, fewer drug interactions, and ease of use since anticoagulant monitoring is not required. Current perioperative management will be affected by these characteristics, with the potential to obviate the need for heparin bridging. This review aims to summarize the current evidence of perioperative thromboembolic and bleeding risk during anticoagulant interruption, which is derived predominantly from patients receiving VKA therapy, and early studies involving NOACs which mainly focus on patients who are receiving dabigatran. The role of heparin bridging is discussed. We also provide a practical approach for the perioperative management of patients who are receiving NOAC therapy.

Publication metadata

Author(s): Liew A, Douketis J

Publication type: Review

Publication status: Published

Journal: Internal and Emergency Medicine

Year: 2013

Volume: 8

Issue: 6

Pages: 477-484

Print publication date: 01/09/2013

ISSN (print): 1828-0447

ISSN (electronic): 1970-9366

URL: http://dx.doi.org/10.1007/s11739-013-0963-5

DOI: 10.1007/s11739-013-0963-5

PubMed id: 23807281

Share